A phase II clinical trial using the PD-L1 inhibitor Durvalumab as third-line therapy for advanced NSCLC showed that the drug in NSCLC with EGFR−/ALK− was more effective than that in NACLC with EGFR+/ALK+ regardless of PD-L1 expression (36). This evidence concerns the gene ALK and non-small cell lung carcinoma.